Duncan Bridgeman
Friday 14th November 2003 |
Text too small? |
However, a policy change in accounting for foreign exchange hedges made comparisons with the same period a year ago misleading.
F&P Healthcare shares traded early yesterday at $12.05, down 20c since the interim profit announcement on Wednesday.
While net profit fell to $25.2 million, revenue growth from new products climbed 27% in US dollar terms, pushing operating revenue up 3.8% to a record $104.9 million.
The company is forecasting full year revenue of between $US120 million ($193.5 million) and $US125 million.
ABN Amro said in a research note it was reviewing its target price of $13.14 and its add recommendation on the stock. The broking house noted that the company's new obstructive sleep apnoea (OSA) flow generators would be fully established in the second half of the current financial year while its new mask products should continue to increase consumables market sha
No comments yet
PaySauce Quarterly Market Update - Dec 2024
CHI - FY24 Results Date and Audio Conference Details
AIA - December 2024 Monthly traffic update
January 15th Morning Report
PF - Details of Interim Results Webcast
Scott Secures NZ$18 million in Global Contracts for Protein
January 14th Morning Report
AFT - NEW YEAR LETTER TO INVESTORS
TruScreen Invited to Present WHO AI Collaboration Meeting
January 13th Morning Report